wire - news in brief
« BACK
Pharmacology - Health - 14.01.2021
Health - Pharmacology - 12.01.2021
Pharmacology - Health - 12.01.2021
Health - Pharmacology - 11.01.2021
Pharmacology - Health - 11.01.2021
Health - Pharmacology - 05.01.2021
Pharmacology - Health - 19.12.2020
Health - Pharmacology - 19.12.2020
Life Sciences - Pharmacology - 18.12.2020 
A weather station for epileptic seizure
The unpredictability of epileptic seizures is a severe handicap for patients.
Pharmacology - Health - 18.12.2020
Health - Pharmacology - 17.12.2020
Pharmacology - Health - 16.12.2020
Pharmacology - Health - 16.12.2020
Health - Pharmacology - 15.12.2020 
New synthetic molecule can kill the flu virus
Scientists have developed a synthetic molecule capable of killing the virus that causes influenza. They hope their discovery will lead to an effective drug treatment.
Pharmacology - Health - 15.12.2020
Health - Pharmacology - 14.12.2020
Pharmacology - Health - 11.12.2020
Health - Pharmacology - 11.12.2020
Health - Pharmacology - 10.12.2020
Health - Pharmacology - 09.12.2020
Health - Pharmacology - 09.12.2020
Research Management - Pharmacology - 09.12.2020
Pharmacology - Health - 08.12.2020
Pharmacology - 08.12.2020
Pharmacology - Health - 08.12.2020
Pharmacology - Health - 07.12.2020
Pharmacology - Health - 05.12.2020
Pharmacology - Health - 04.12.2020
Health - Pharmacology - 02.12.2020
Health - Pharmacology - 02.12.2020
Health - Pharmacology - 30.11.2020 
Taco mattresses take the pressure off hospitals
During the lockdown last spring, Julian Ferchow put his doctoral project aside to help relieve the strain on hospitals.
Health - Pharmacology - 25.11.2020 
Infusion more effective than tablets: Treatment of iron anaemia in rural Africa
Iron-deficiency anaemia is a major concern in low income countries, especially for women. A study conducted in Tanzania has now demonstrated the advantage of iron infusion therapy over the usual treatment with iron tablets.
Health - Pharmacology - 25.11.2020
Health - Pharmacology - 24.11.2020
Pharmacology - Health - 24.11.2020
Pharmacology - Health - 19.11.2020
Pharmacology - Health - 19.11.2020
Health - Pharmacology - 18.11.2020
Pharmacology - Health - 13.11.2020
Pharmacology - Health - 13.11.2020
Pharmacology - Health - 13.11.2020
Health - Pharmacology - 06.11.2020
Pharmacology - Event - 05.11.2020
Pharmacology - Health - 05.11.2020
Pharmacology - Health - 02.11.2020
Health - Pharmacology - 30.10.2020 
Contact tracing with prophylactic treatment could near-eliminate leprosy
Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programmes, and is generally well accepted by patients, their contacts, and healthcare workers.
Pharmacology - Health - 30.10.2020
Pharmacology - Health - 30.10.2020
Pharmacology - Health - 29.10.2020
Health - Pharmacology - 29.10.2020
Pharmacology
Results 1 - 50 of 1523.
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently th
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently th
Second COVID-19 vaccine approved for Switzerland
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.
New Ebolavirus treatment sees the light thanks to basic research performed in Ticino
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treament against another well-known virus, much less widespread but extremely lethal: Ebola.
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treament against another well-known virus, much less widespread but extremely lethal: Ebola.
Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland
Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits Swissmedic has authorised the vaccine from Pfizer/BioNTech.
Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits Swissmedic has authorised the vaccine from Pfizer/BioNTech.
The unpredictability of epileptic seizures is a severe handicap for patients.
Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients' quality of life 1-3 C3 glomerulopathy (C3G) is a
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients' quality of life 1-3 C3 glomerulopathy (C3G) is a
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto to treat patients with HFpEF
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval co
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval co
Scientists have developed a synthetic molecule capable of killing the virus that causes influenza. They hope their discovery will lead to an effective drug treatment.
Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infection Roche will be able to ramp up to a double-digit million number
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infection Roche will be able to ramp up to a double-digit million number
Novartis Kisqali demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with un rivaled OS evidence 1 Kisqali plus endocrine therapy had a median OS of nearly five years (58&peri
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with un rivaled OS evidence 1 Kisqali plus endocrine therapy had a median OS of nearly five years (58&peri
Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
Moderna's vaccine triggers an antibody response to the SARS-CoV-2 spike protein The Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine tri
Moderna's vaccine triggers an antibody response to the SARS-CoV-2 spike protein The Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine tri
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif * in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibito
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibito
Roche presents new data from its bispecific antibody portfolio across a range of blood cancers
Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, an
Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, an
Novartis analyses confirm benefit of Kymriah with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83% 1 L
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83% 1 L
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies
Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein The spike protein is the target of many COVID-19 vaccines in development This test may help identif
Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein The spike protein is the target of many COVID-19 vaccines in development This test may help identif
During the lockdown last spring, Julian Ferchow put his doctoral project aside to help relieve the strain on hospitals.
Iron-deficiency anaemia is a major concern in low income countries, especially for women. A study conducted in Tanzania has now demonstrated the advantage of iron infusion therapy over the usual treatment with iron tablets.
Tackling pandemic threats proactively
If we are to minimize the impact of future disease outbreaks, we must recognize the importance of immunization and invest in preemptive vaccine development, writes Tim Keys.
If we are to minimize the impact of future disease outbreaks, we must recognize the importance of immunization and invest in preemptive vaccine development, writes Tim Keys.
Coronavirus: simplified, faster generation of SwissCovid app codes
The process of generating covidcodes has been significantly simplified and accelerated. Persons who have tested positive can enter their code into the SwissCovid app to inform other app users of possible exposure to the virus.
The process of generating covidcodes has been significantly simplified and accelerated. Persons who have tested positive can enter their code into the SwissCovid app to inform other app users of possible exposure to the virus.
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult p
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult p
Results from real-world data and post-hoc analysis of Novartis Beovu pivotal trials presented at AAO 2020
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD 1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commi
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD 1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commi
Novartis provides update on CAN-COVID trial in hospitalized patients
The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilatio
The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilatio
Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx at Week 12 vs.
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx at Week 12 vs.
Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programmes, and is generally well accepted by patients, their contacts, and healthcare workers.
Novartis presents latest Phase III data reinforcing Cosentyx as a first-line systemic treatment in pediatric psoriasis
Latest data show Cosentyx provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile 1,2 Moderate-to-severe psoriasis affects more than 350,0
Latest data show Cosentyx provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile 1,2 Moderate-to-severe psoriasis affects more than 350,0
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
Acquisition expands the Novartis footprint in ophthalmology and enhances the company's position as an AAV-based gene therapy powerhouse.
Acquisition expands the Novartis footprint in ophthalmology and enhances the company's position as an AAV-based gene therapy powerhouse.
